Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Trevi Therapeutics Inc (TRVI) USD0.001

Sell:$1.35 Buy:$1.38 Change: $0.0197 (1.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0197 (1.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0197 (1.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat neurologically mediated conditions. The Company is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). It is also developing Haduvio in levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. It is conducting a Phase 2b/3 clinical trial of Haduvio in patients with severe pruritus associated with prurigo nodularis. It is also conducting a Phase 2 clinical trial of Haduvio for chronic cough in patients with IPF. It has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus, Pruritus in Chronic Liver Disease and Uremic Pruritus Programs.

Contact details

195 Church St Fl 14
United States
+1 (203) 3042499

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$29.59 million
Shares in issue:
21.60 million
United States
US dollar

Key personnel

  • David Meeker
    Chairman of the Board
  • Jennifer Good
    President, Chief Executive Officer, Director
  • Thomas Sciascia
    Co-Founder, Chief Medical Officer
  • Lisa Delfini
    Chief Financial Officer
  • Danine Summers
    Vice President - Medical Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.